PDCD1 and cancer: The blockade of the PD1/PDL1 axis by anti-PDL1 could affect antitumor immune response and suppress tumor growth since it was first demonstrated in the PDL1+ mouse model in 2002, providing attractive targets for cancer immunotherapy (Dong et al., 2002).